Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Interest & Investment Income (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Interest & Investment Income for 6 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 36.37% to $5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.0 million through Dec 2025, down 22.19% year-over-year, with the annual reading at $27.0 million for FY2025, 22.19% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $5.7 million at Relay Therapeutics, down from $6.4 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $9.0 million in Q4 2024, with the low at $157000.0 in Q3 2021.
  • Average Interest & Investment Income over 5 years is $5.1 million, with a median of $6.7 million recorded in 2023.
  • The sharpest move saw Interest & Investment Income tumbled 85.62% in 2021, then skyrocketed 1911.99% in 2022.
  • Over 5 years, Interest & Investment Income stood at $267000.0 in 2021, then surged by 1911.99% to $5.4 million in 2022, then soared by 61.95% to $8.7 million in 2023, then grew by 3.15% to $9.0 million in 2024, then plummeted by 36.37% to $5.7 million in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $5.7 million, $6.4 million, and $7.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.